New Delhi: Aarti Drugs on Tuesday said its two manufacturing facilities have received import alert from the US Food and Drug Administration, a development which could impact the company's exports to the American market.
"Two of the Aarti Drugs facilities in Tarapur have received an import alert dated March 23, 2015 as per the US Food and Drug Administration (USFDA) website," the drug firm said in a filing to the BSE.
(Also read: Aarti Drugs stock falls on FDA import alert)
The company, however, added that only one of the two plants is an FDA-compliant facility.
"Second one, we had already delisted from the USFDA website couple of years back," it added.
The company said for the E-22 facility, it had a re-inspection in August 2014 and after that, the company submitted four responses starting August 2014 and the last response in February 2015.
"We still have to receive an official communication from USFDA on the import alert after which we can take immediate actions to rectify the same," it added.
The drug firm said the import alert would not impact the company much as US sales contribute less than 1 per cent of the company's total sales volume.
"For the current financial year 2014-15, the total US sales contributes to slightly less than 1 per cent of the total sales volume. Hence this shouldn't affect our top-line and bottom-line significantly," it added.
Shares in Aarti Drugs the company, on Tuesday, ended at Rs 626.25 apiece on the BSE, down 7.03 per cent from the previous close.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
